Traders should monitor the April 22 conference call and AAN presentations closely—positive data, especially durable remission rates or strong safety in SPS, could catalyze substantial upside. Given the lack of approved SPS therapies and miv-cel's potential first-in-class status, even modest efficacy could be viewed favorably. However, safety signals or underwhelming response durability could trigger downside volatility.
Price Chart
Executive Summary
Kyverna Therapeutics announced upcoming oral presentations at the AAN Annual Meeting detailing primary analysis from its KYSA-8 registrational trial of miv-cel in stiff person syndrome (SPS) and updated Phase 2 data from KYSA-6 in generalized myasthenia gravis (gMG). The company will host a conference call on April 22, 2026, to discuss these data, marking a critical readout for its lead asset in two rare autoimmune diseases with no approved therapies.
Key Facts
- Kyverna will present primary analysis from the KYSA-8 registrational trial of miv-cel in stiff person syndrome (SPS) at AAN 2026.
- Longer-term follow-up data from the KYSA-6 Phase 2 trial in generalized myasthenia gravis (gMG) will also be presented.
- Both presentations are oral late-breaker and update sessions at a major neurology conference, indicating clinical significance.
- Miv-cel is a fully human CD19 CAR T-cell therapy being evaluated for durable remission in B-cell-driven autoimmune diseases with a single infusion.
- There are no FDA-approved treatments for SPS, and miv-cel represents a potentially first-in-class therapy for both SPS and gMG.
Financial Impact
High optionality value in a $557M market cap company; successful data could support BLA submission and significantly revalue the stock.
Risk Factors
- Clinical data may not meet expectations, particularly in a small, heterogeneous SPS population.
- Regulatory path remains uncertain—FDA may require additional trials before accepting a BLA.
- Dilution risk if future funding needs arise ahead of commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270858 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.25 (−10.03%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.25 (−24.96%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.25 (−34.84%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.25 (−34.84%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.25 (−33.77%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.25 (−46.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.25 (+34.88%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.25 (−41.72%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.25 (−48.73%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.25 (−53.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers